MarketMoodz
EU Approves Sanofi MS Drug Cenrifki Despite FDA Rejection
The European Commission approved Cenrifki (tolebrutinib) for adults with non‑relapsing secondary progressive multiple sclerosis (nrSPMS) who have not had relapses in the prior two years, granting Sanofi a foothold in the European MS market. The decision contrasts with a U.S. FDA complete response letter that flagged risks of severe drug‑induced liver injury and requires a risk‑mitigation plan before approval in the United States.
Key Takeaways
- The European Commission approved Cenrifki (tolebrutinib) for adults with nrSPMS without relapses in the prior two years.
- Approval rested on Phase 3 HERCULES plus supporting GEMINI 1 and GEMINI 2 data.
- The U.S. FDA issued a complete response letter citing risk of severe drug‑induced liver injury and asked for a risk‑mitigation plan.
- Sanofi took a reported €1.66 billion write‑down on tolebrutinib alongside 2025 results and plans a Germany launch later this year.
- Japan approved Wayrilz (rilzabrutinib) for persistent and chronic ITP, signaling pipeline momentum outside MS.
People Involved
- No specific individuals mentioned
Entities Involved
- Sanofi SA (SNY)Developer and marketer of Cenrifki (tolebrutinib) and sponsor of the Phase 3 trials
- European CommissionRegulatory authority that approved Cenrifki for nrSPMS in the EU
- U.S. Food and Drug Administration (FDA)Regulatory authority that issued a complete response letter citing DILI risk
- Ministry of Health, Labour and Welfare (Japan) (MHLW)Regulatory authority that approved Wayrilz (rilzabrutinib) for ITP
- HERCULES (Phase 3 trial)Pivotal Phase 3 study supporting Cenrifki efficacy in nrSPMS
- GEMINI 1 (Phase 3 trial)Phase 3 trial supporting tolebrutinib in relapsing MS
- GEMINI 2 (Phase 3 trial)Phase 3 trial supporting tolebrutinib in relapsing MS
- Cenrifki (tolebrutinib)Sanofi's BTK inhibitor approved in the EU for nrSPMS
- Wayrilz (rilzabrutinib)BTK inhibitor approved in Japan for persistent and chronic ITP
MarketMoodz Analysis
For investors, the European Commission approval materially lifts Cenrifki's revenue optionality in Europe even as U.S. prospects dim. EU access allows Sanofi to begin commercial roll‑out, negotiate national pricing and reimbursement, and generate real‑world safety data that could influence future regulatory talks; Sanofi's plan to launch in Germany later this year targets one of Europe's largest MS markets. At the same time, the FDA's complete response letter over drug‑induced liver injury creates a hard barrier to U.S. sales without an accepted risk‑mitigation strategy, and the reported €1.66 billion write‑down signals management has lowered the probability of approval and valued that risk into near‑term results.
This episode underscores regulatory divergence between the EMA/EC and FDA—different risk‑benefit judgments can produce split outcomes that materially affect market access and valuation. Investors should watch three things next: the EMA's approved label and post‑marketing safety commitments (which will set monitoring and usage constraints in Europe), Sanofi's submissions and proposed risk‑mitigation plan to the FDA, and early uptake and real‑world liver‑safety signals from initial European use. Separately, Japan's MHLW approval of Wayrilz points to momentum in Sanofi's BTK inhibitor program beyond MS and could partially offset investor concerns if commercial uptake and safety profiles remain acceptable.
Source: Original Article